Jerusalem, Israel, February 6, 2018 – Immunity Pharma, a clinical-stage neurology-focused biopharmaceutical company, announced today that the Israel's Ministry of Health (MOH) has approved the clinical protocol for its extended Phase 2a Amyotrophic Lateral Sclerosis (ALS) study. The approval is for the continued treatment of ALS patients via intravenously administered IPL344 as a follow-up study to an open-label, dose-escalating Phase 1/2a study. The extended Phase 2a study will assess the safety, tolerability, and efficacy of intravenously administrated IPL344 for the treatment of ALS. The initial one-month Phase 1/2a study was previously approved by the Ministry of Health.
"Obtaining approval for our Phase 2a ALS study from the Israeli MOH is a major step towards testing the efficacy of IPL344 in patients. We are looking forward towards starting this clinical trial which goal is to demonstrate that IPL344 significantly slows ALS disease progression" said Eran Ovadia, Immunity Pharma's founder and CEO.
"We believe that IPL344 represents a new therapeutic concept that may help patients who suffer not only from ALS but also from other neurodegenerative diseases. We plan to test IPL344 in a variety of such diseases in the future" said Dr. Ilana Cohen, Immunity Pharma's VP, Research and Development.
IPL344 is Immunity Pharma lead drug candidate. IPL344 activates the PI3K-Akt signaling pathway in a variety of cells, including neurons, inducing pro-survival and anti-inflammatory processes. IPL344 is being developed as an intravenous injection for the treatment of ALS. IPL344 is planned to enter an open-label Phase 1/2a clinical trial in ALS patients.
About Immunity Pharma
Immunity Pharma Ltd. (IPL) is a privately-held clinical-stage neurology-focused biopharmaceutical company that develops therapies for neurodegenerative diseases, with an initial focus on Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. IPL’s drugs are biologically active peptides that stimulate therapeutic cell-signaling processes which are down-regulated in neurodegenerative diseases. These drugs mitigate progression of neurodegenerative diseases by inducing survival-supporting processes, including reduction of inflammation and reduction of programed cell death (apoptosis).
For more information please visit www.immunitypharma.com